Lupin receives EIR from USFDA for Mandideep Unit II facility

15 Apr 2020 Evaluate

Lupin has received the Establishment Inspection Report (EIR) after closure of the United States Food and Drug Administration (USFDA) inspection of its Mandideep Unit II facility, classifying the inspection as Voluntary Action Indicated. The inspection at the facility was carried out by the USFDA between November 26, 2018 and December 4, 2018.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2093.80 -27.85 (-1.31%)
29-Jan-2026 10:16 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1586.80
Dr. Reddys Lab 1192.90
Cipla 1309.45
Zydus Lifesciences 883.95
Lupin 2093.80
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×